Upregulation of AIB1, aromatase and ERα provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival

Hormone Molecular Biology and Clinical Investigation

Volumn 3, Issue 1, 2010, Pages 357-366

  Tilghman, Syreeta L ^a   Sabnis, Gauri ^a   Brodie, Angela M H ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Room 4 002 ^*  (United States)

Author keywords

aromatase; breast cancer; coactivators; estrogen receptor; long term estrogen deprivation

Indexed keywords

ANDROSTENEDIONE; ANTIESTROGEN; AROMATASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LETROZOLE; STEROID; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; LONG TERM CARE; MCF-7 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT DURATION; UPREGULATION;

EID: 84884370282     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.042     Document Type: Article

References (19)

1. Litherland S., Jackson IM. Antiestrogens in the management of hormone-dependent breast cancer. Cancer Treat Rev 1988;15: 183-94.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal., cytotoxic or immune therapy: 133 randomized trials among 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:71-85.
3. ATAC Trialists' Group. The ATAC (Arimidex., Tamoxifen., Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res Treat 2001;69:210.
4. Baum M., Buzdar AU., Cuzick J., Forbes J., Houghton JH., Klijn JG., Sahmoud T., for the ATAC (Arimidex., Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359: 2131-9.
5. Coombes RC., Hall E., Gibson LJ., Paridaens R., Jassem J., Delozier T., Jones SE., Alvarez I., Bertelli G., Ortmann O., Coates AS., Bajet-ta E., Dodwell D., Coleman RE., Fallowfield LJ., Mickiewicz E., Andersen J., Lonning PE., Cocconi G., Stewart A., Stuart N., Snow-don CF., Carpentieri M., Massimini G., Bliss JM., Intergroup Exe-mestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
6. Xu J., Liao L., Ning G., Yoshida-Komiya H., Deng C., O'Malley BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/ AIB1/ACTR/TRAM-1) is required for normal growth., puberty., female reproductive function., and mammary gland development. Proc Natl Acad Sci USA 2000;97:6379-84.
7. Hudelist G., Czerwenka K., Kubista E., Marton E., Pischinger K., Singer CF. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 2003;78: 193-204.
8. Oñate SA., Tsai SY., Tsai MJ., O'Malley BW. Sequence and characterization of a coactivator for the steroid receptor superfamily. Science 1995;270:1354-7.
9. Anzick S., Kononen J., Walker RL., Azorosa DO., Tanner MM., Guan X., Sauter G., Kallioniemi O., Trent JM., Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-7.
10. Jelovac D., Sabnis G., Long BJ., Macedo L., Goloubeva OG., Brodie AMH. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005;65:5380-9.
11. Masumara S., Santner SJ., Heitjan DF., Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
12. Long BJ., Jelovac D., Thiantanawat A., Brodie AM. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmeno-pausal breast cancer model. Clin Cancer Res 2002;8:5092-5.
13. Sabnis G., Jelovac D., Long BJ., Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-10.
14. Barile FA. Cellular methods of general toxicity. In: Barile FA., editor. Introduction to in vitro cytotoxicology mechanisms and methods. Florida: CRC Press., 1994:54-5.
15. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271-7.
16. Mossmann T. Rapid colorimetric assay for cellular growth and survival: application and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
17. List H-J., Reiter R., Singh B., Wellstein A., Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001;68:21-8.
18. Osborne C., Bardou V., Hopp TA., Chamness GC., Hilsenbeck SG., Fuqua SAW., Wong J., Allred DC., Clark GM., Schiff R. Role of the ER coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95: 353-61.
19. Song R-X., McPherson RA., Adam L., Bao Y., Shupnik M., Kumar R., Santen RJ. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002;16:116-27.